Daiichi Sankyo Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 1262
- Registration Number
- NCT00680953
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT00575471
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT00575874
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 577
- Registration Number
- NCT00141453
© Copyright 2024. All Rights Reserved by MedPath